In Phase III Trial, Amrubicin Improved Response Rate and Progression-Free Survival Vs. Topotecan

by Kathy Jones on  July 10, 2011 at 9:14 PM Clinical Trials News
RSS Email Print This Page Comment
Font : A-A+

Research presented at the 14th World Conference on Lung Cancer in Amsterdam says that lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin). The meet is hosted by the International Association for the Study of Lung Cancer (IASLC).
 In Phase III Trial, Amrubicin Improved Response Rate and Progression-Free Survival Vs. Topotecan
In Phase III Trial, Amrubicin Improved Response Rate and Progression-Free Survival Vs. Topotecan

"Amrubicin showed significant improvements in tumor shrinkage, symptom control and progression-free survival over topotecan without improving overall survival, the primary endpoint of the trial," said principal investigator Dr. Joachim von Pawel, of the Asklepios Hospital Munich-Gauting in Germany. "However, for patients with the most difficult-to-treat small cell lung cancer, amrubicin offered an improvement in overall survival compared with topotecan."

Second-line treatment is given to patients after the initial, or first-line, treatment has failed.

In the study, 637 patients were randomized to amrubicin or to topotecan. Patients on amrubicin reported better symptom control and quality of life (Lung Cancer Symptom Scale 0.2 vs 5.6 and LCSS-SB -0.1 vs 5.2 for amrubicin and topotecan, respectively). They also reported fewer adverse events, including neutropenia (41% vs 53% for the topotecan arm), thrombocytopenia (21% vs 54%), anemia (16% vs 30%), infections (16% vs 10%), febrile neutropenia (10% vs 4%), all P<0.05, and cardiac disorders (5% vs 5%; P=0.84).



Source: Eurekalert

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive